Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: Biological implications for targeted therapy opportunities

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Jardim, Denis L Fontes ^a   Conley, Anthony ^a   Subbiah, Vivek ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Breast sarcoma; Chemotherapy; CLIA; Immunohistochemistry; Morphoproteomics; Mutation; Next generation sequencing; NRAS; P13K; P53; Phyllodes sarcoma; Phyllodes tumor; Proteomics; Rare disease; Sarcoma; SPARC; Targeted therapy; TLE3; Whole genome sequencing

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; OSTEONECTIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; PROTEIN P53; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN;

ADULT; ARTICLE; CASE REPORT; CHROMOSOME 1; COMPARATIVE GENOMIC HYBRIDIZATION; CYSTOSARCOMA PHYLLOIDES; CYTOPLASM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE MUTATION; GENOMICS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAW; MASTECTOMY; MEDICAL RECORD REVIEW; ONCOGENE N RAS; PROTEOMICS; RETROSPECTIVE STUDY; BREAST TUMOR; GENETICS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; SECONDARY;

BREAST NEOPLASMS; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; MIDDLE AGED; PHYLLODES TUMOR; PROTEOMICS;

EID: 84883263667     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-112     Document Type: Article

References (31)

1. Phyllodes tumors of the breast: a review of 32 cases. Geisler DP, Boyle MJ, Malnar KF, McGee JM, Nolen MC, Fortner SM, Broughan TA, Am Surg 2000 66 4 360 366 10776873 (Pubitemid 30210750)
2. Fibroepithelial tumours. Bellocq JP, Magro G, World Health Organization classification of tumours: Pathology and genetics tumours of the breast and female genital organs Lyon: IARC Press, Tavassoli FAD,P, 2003 99 103
3. The clinical and histologic criteria that predict metastases from cystosarcoma phyllodes. Hawkins RE, Schofield JB, Fisher C, Wiltshaw E, McKinna JA, Cancer 1992 69 1 141 147 10.1002/1097-0142(19920101)69:1<141::AID- CNCR2820690125>3.0.CO;2-1 1309302
4. Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. Moffat CJ, Pinder SE, Dixon AR, Elston CW, Blamey RW, Ellis IO, Histopathology 1995 27 3 205 218 10.1111/j.1365-2559.1995.tb00212.x 8522284
5. Phyllodes tumour of the breast: a retrospective analysis of 30 cases. Mokbel K, Price RK, Mostafa A, Wells CA, Carpenter R, Breast 1999 8 5 278 281 10.1054/brst.1999.0058 14965745
6. Malignant phyllodes tumours of the breast. A clinical and pathological analysis of 55 cases. Reinfuss M, Mitus J, Smolak K, Stelmach A, Eur J Cancer 1993 29A(9 1252 1256 (Pubitemid 23169891)
7. Malignant phyllodes tumor composed almost exclusively of a fibrosarcomatous component: a case report and review of malignant phyllodes tumors with metastases. Suzuki-Uematsu S, Shiraishi K, Ito T, Adachi N, Inage Y, Taeda Y, Ueki H, Ohtani H, Breast cancer (Tokyo, Japan) 2010 17 3 218 224 10.1007/s12282-009-0099-7
8. Risk factors for recurrence and death after primary surgical treatment of malignant phyllodes tumors. Asoglu O, Ugurlu MM, Blanchard K, Grant CS, Reynolds C, Cha SS, Donohue JH, Ann Surg Oncol 2004 11 11 1011 1017 10.1245/ASO.2004.02.001 15525831 (Pubitemid 40486668)
9. Phyllodes tumor of the breast. Belkacemi Y, Bousquet G, Marsiglia H, Ray-Coquard I, Magne N, Malard Y, Lacroix M, Gutierrez C, Senkus E, Christie D, et al. Int J Radiat Oncol Biol Phys 2008 70 2 492 500 10.1016/j.ijrobp.2007.06. 059 17931796
10. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Macdonald OK, Lee CM, Tward JD, Chappel CD, Gaffney DK, Cancer 2006 107 9 2127 2133 10.1002/cncr.22228 16998937 (Pubitemid 44665645)
11. Long-term outcomes of malignant phyllodes tumors patients: an institutional experience. Fou A, Schnabel FR, Hamele-Bena D, Wei XJ, Cheng B, El Tamer M, Klein L, Joseph KA, Am J Surg 2006 192 4 492 495 10.1016/j.amjsurg. 2006.06.017 16978957 (Pubitemid 44362984)
12. Cystosarcoma phyllodes. Effective therapy with cisplatin and etoposide chemotherapy. Burton GV, Hart LL, Leight GS Jr, Iglehart JD, McCarty KS Jr, Cox EB, Cancer 1989 63 11 2088 2092 10.1002/1097-0142(19890601)63:11<2088::AID- CNCR2820631103>3.0.CO;2-C 2541882 (Pubitemid 19136835)
13. Successful chemotherapy for cystosarcoma phyllodes in a young woman. Allen R, Nixon D, York M, Coleman J, Arch Intern Med 1985 145 6 1127 1128 10.1001/archinte.1985.00360060195030 2988474 (Pubitemid 15041352)
14. Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes. Hawkins RE, Schofield JB, Wiltshaw E, Fisher C, McKinna JA, Cancer 1992 69 9 2271 2275 10.1002/1097-0142(19920501)69:9<2271::AID- CNCR2820690911>3.0.CO;2-7 1314127
15. Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast. Morales-Vasquez F, Gonzalez-Angulo AM, Broglio K, Lopez-Basave HN, Gallardo D, Hortobagyi GN, De La Garza JG, Breast J 2007 13 6 551 556 10.1111/j.1524-4741. 2007.00510.x 17983394 (Pubitemid 350064023)
16. Gain in 1q is a common abnormality in phyllodes tumours of the breast. Jee KJ, Gong G, Ahn SH, Park JM, Knuutila S, Anal cell pathol: J Euro Society for Anal Cell Pathol 2003 25 2 89 93 (Pubitemid 36443409)
17. Phyllodes tumors of the breast analyzed by comparative genomic hybridization and association of increased 1q copy number with stromal overgrowth and recurrence. Lu YJ, Birdsall S, Osin P, Gusterson B, Shipley J, Genes Chromosomes Cancer 1997 20 3 275 281 10.1002/(SICI)1098-2264(199711)20: 3<275::AID-GCC8>3.0.CO;2-# 9365835 (Pubitemid 27484103)
18. Overexpression of Cks1 is associated with poor survival by inhibiting apoptosis in breast cancer. Wang XC, Tian LL, Tian J, Wu HL, Meng AM, J Cancer Res Clin Oncol 2009 135 10 1393 1401 10.1007/s00432-009-0582-8 19352700
19. A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. Jones AM, Mitter R, Springall R, Graham T, Winter E, Gillett C, Hanby AM, Tomlinson IP, Sawyer EJ, Phyllodes Tumour C, J Pathol 2008 214 5 533 544 10.1002/path.2320 18288784 (Pubitemid 351482269)
20. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Perot G, Chibon F, Montero A, Lagarde P, De The H, Terrier P, Guillou L, Ranchere D, Coindre JM, Aurias A, Am J Pathol 2010 177 4 2080 2090 10.2353/ajpath.2010.100104 20884963
21. p53 protein expression and gene mutation in phyllodes tumors of the breast. Gatalica Z, Finkelstein S, Lucio E, Tawfik O, Palazzo J, Hightower B, Eyzaguirre E, Pathol Res Pract 2001 197 3 183 187 10.1078/0344-0338-00031 11314782 (Pubitemid 32273376)
22. Immunohistochemical and molecular markers in breast phyllodes tumors. Korcheva VB, Levine J, Beadling C, Warrick A, Countryman G, Olson NR, Heinrich MC, Corless CL, Troxell ML, Appl Immunohistochem Mol Morphol: AIMM/official publication of the Society for Appl Immunohistochem 2011 19 2 119 125 10.1097/PAI.0b013e3181f5349a
23. RAS oncogenes: weaving a tumorigenic web. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D, Nat Rev Cancer 2011 11 11 761 774 10.1038/nrc3106 21993244
24. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, Van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Lancet Oncol 2013 14 249 256 10.1016/S1470-2045(13)70024-X 23414587
25. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, et al. Proceedings of the National Academy of Sciences of the United States of America 2013
26. TLE3 as a candidate biomarker of response to taxane therapy. Kulkarni SA, Hicks DG, Watroba NL, Murekeyisoni C, Hwang H, Khoury T, Beck RA, Ring BZ, Estopinal NC, Schreeder MT, et al. Breast cancer res: BCR 2009 11 2 17 10.1186/bcr2241 19309506
27. Albumin-bound paclitaxel: a next-generation taxane. Gradishar WJ, Expert Opin Pharmacother 2006 7 8 1041 1053 10.1517/14656566.7.8.1041 16722814 (Pubitemid 43949942)
28. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Desai N, Trieu V, Damascelli B, Soon-Shiong P, Transl Oncol 2009 2 2 59 64 19412420
29. Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases. Tse GM, Lee CS, Kung FY, Scolyer RA, Law BK, Lau TS, Putti TC, Am J Clin Pathol 2002 118 4 522 526 10.1309/D206-DLF8-WDNC-XJ8K 12375638 (Pubitemid 46098498)
30. Platelet-derived growth factor expression in phyllodes tumors and fibroadenomas of the breast. Feakins RM, Wells CA, Young KA, Sheaff MT, Hum Pathol 2000 31 10 1214 1222 10.1053/hupa.2000.18481 11070114
31. Major response to sunitinib (Sutene) in metastatic malignant phyllodes tumor of breast. Park IH, Kwon Y, Kim EA, Lee KS, Ro J, Invest New Drugs 2009 27 4 387 388 10.1007/s10637-008-9195-3 19002383